Dr. Dagmar Hess
Medizinische Onkologie und Hämatologie · Dept. I
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Jörger M, Alonso G, Goebeler M, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz M, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo J, Koster K, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt A, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle P, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll F, Wild P, Chun F, Reis H, Lloyd P, Machacek M, Gajewski T, Fridman W, Eggermont A, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, Dantas-Silva A, Lichtenegger F, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2024
Dec 11, 2024Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Dec 11, 2024Nature 2024
Melero Ignacio, de Miguel Luken Maria, de Velasco Guillermo, Garralda Elena, Martin-Liberal Juan, Jörger Markus, Alonso Guzman, Goebeler Maria-Elisabeth, Schuler Martin, König David, Dummer Reinhard, Reig Maria, Rodriguez Ruiz Maria-Esperanza, Calvo Emiliano, Esteban-Villarrubia Jorge, Oberoi Arjun, Sabat Paula, Soto-Castillo Juan José, Koster Kira-Lee, Saavedra Omar, Sayehli Cyrus Michael, Gromke Tanja, Läubli Heinz, Ramelyte Egle, Fortuny Marta, Landa-Magdalena Ana, Moreno Irene, Torres-Jiménez Javier, Hernando-Calvo Alberto, Hess Dagmar, Racca Fabricio, Richly Heike, Schmitt Andreas Michael, Eggenschwiler Corinne, Sanduzzi-Zamparelli Marco, Vilalta-Lacarra Anna, Trojan Jörg, Koch Christine, Galle Peter R, Foerster Friedrich, Trajanoski Zlatko, Hackl Hubert, Gogolla Falk, Koll Florestan J, Wild Peter J, Chun Felix Kyoung Hwan, Reis Henning, Lloyd Peter, Machacek Matthias, Gajewski Thomas F, Fridman Wolf H, Eggermont Alexander M M, Bargou Ralf C, Schöniger Sandra, Rüschoff Josef, Tereshchenko Anastasiia, Zink Carina, Dantas-Silva Amanda, Lichtenegger Felix S, Akdemir Julia, Rüdiger Manfred, L'Huillier Phil, Dutta Aradhana, Haake Markus, Auckenthaler Alexandra, Gjorgjioska Ana, Rössler Bernhard, Hermann Frank, Liebig Mara, Reichhardt Daniela, Schuberth-Wagner Christine, Wischhusen Jörg, Fettes Petra, Auer Marlene, Klar Kathrin, Leo Eugen
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol 2024; 94:349-360.
Jun 15, 2024Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Jun 15, 2024Cancer Chemother Pharmacol 2024; 94:349-360
Mc Laughlin Anna M, Hess Dagmar, Michelet Robin, Colombo Ilaria, Haefliger Simon, Bastian Sara, Rabaglio-Poretti Manuela, Schwitter Michael, Fischer Stefanie, Eckhardt Katrin, Hayoz Stefanie, Kopp Christoph, Klose Marian, Sessa Cristiana, Stathis Anastasios, Halbherr Stefan, Huisinga Wilhelm, Jörger Markus, Kloft Charlotte
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer 2024; 201:113588.
Feb 2, 2024TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Feb 2, 2024Eur J Cancer 2024; 201:113588
Colombo Ilaria, Koster Kira-Lee, Holer Lisa, Haefliger Simon, Rabaglio-Poretti Manuela, Bastian Sara, Schwitter Michael, Eckhardt Katrin, Hayoz Stefanie, Mc Laughlin Anna M, Kloft Charlotte, Klose Marian, Halbherr Stefan, Baumgartner Christian, Sessa Cristiana, Stathis Anastasios, Hess Dagmar, Jörger Markus
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun 2023; 3:1853-1861.
Sep 14, 2023A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Sep 14, 2023Cancer Res Commun 2023; 3:1853-1861
Hanna Glenn J, Stathis Anastasios, Lopez-Miranda Elena, Racca Fabricio, Quon Doris, Leyvraz Serge, Hess Dagmar, Keam Bhumsuk, Rodón Jordi, Ahn Myung-Ju, Kim Hye Ryun, Schneeweiss Andreas, Ribera Josep-Maria, DeAngelo Daniel, Perez Garcia Jose Manuel, Cortes Javier, Schönborn-Kellenberger Oliver, Weber Dirk, Pisa Pavel, Bauer Michael, Beni Laura, Bobadilla Maria, Lehal Raj, Vigolo Michele, Vogl Florian D, Garralda Elena
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
Jul 12, 2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Jul 12, 2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2021; 63:117-123.
Aug 19, 2021A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Aug 19, 2021Leuk Lymphoma 2021; 63:117-123
Pirosa Maria C, Zhang Lu, Hitz Felicitas, Novak Urban, Hess Dagmar, Terrot Tatiana, Pascale Mariarosa, Mazzucchelli Luca, Bertoni Francesco, Cavalli Franco, Zucca Emanuele, Stathis Anastasios
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Schneeweiss A, Lagkadinou E, Wilkinson G, Boix O, Thiele S, Rudolph M, Rentzsch C, Hurvitz S, Ma C, Tsimberidou A, Moulder S, Varga A, Jörger M, Hess D, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 2019; 11
Dec 10, 2019Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Dec 10, 2019Cancers (Basel) 2019; 11
Schneeweiss Andreas, Lagkadinou Eleni, Wilkinson Gary, Boix Oliver, Thiele Silke, Rudolph Marion, Rentzsch Christine, Hurvitz Sara A, Ma Cynthia, Tsimberidou Apostolia M, Moulder Stacy, Varga Andrea, Jörger Markus, Hess Dagmar, Ocker Matthias
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019
Aug 30, 2019A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Aug 30, 2019Invest New Drugs 2019
Jörger Markus, Sessa Cristiana, Stuedeli Silvia, Levy Nicole, Hafner Peter, Lane Heidi, Larger Patrice, Engelhardt Marc, Kaindl Thomas, Volden Matthias, Mark Michael, Mantiero Mara, Hess Dagmar, Metaxas Yannis, Stathis Anastasios, von Moos Roger
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
Aug 27, 2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Aug 27, 2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 2018; 96:6-16.
Apr 13, 2018First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Apr 13, 2018Eur J Cancer 2018; 96:6-16
Wicki Andreas, Tzankov Alexandar, Hess Viviane, Childs Alexa, Hierro Cinta, Rodón Jordi, Hess Dagmar, Jörger Markus, von Moos Roger, Sessa Cristiana, Ritschard Reto, Prêtre Vincent, Herrmann Richard, Brown Nicholas, Xyrafas Alexandros, Bize Vincent, Hawle Hanne, Berardi Simona, Cmiljanović Nataša, Cmiljanović Vladimir, Stumm Michael, Dimitrijević Saša, Kristeleit Rebecca
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
Mar 20, 2017Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Mar 20, 2017Invest New Drugs 2017; 35:766-772
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C V, Allegrini S, Ackermann C J, Mark M, Jörger Markus, Griguolo G, Homicsko K, von Moos R, Hess Dagmar, Swiss Group for Clinical Cancer Research (SAKK)
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
Dec 19, 2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Dec 19, 2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
Dec 11, 2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Dec 11, 2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
Slingerland M, Valera S, Waldron E, Mu S, Porro M, Loman N, Sandstrom P, Sharma S, Clive S, Hess D, Gelderblom H. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol 2014; 74:1089-98.
Sep 25, 2014A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
Sep 25, 2014Cancer Chemother Pharmacol 2014; 74:1089-98
Slingerland Marije, Valera Sue-Zette, Waldron Edward, Mu Song, Porro Maria G, Loman Niklas, Sandstrom Per, Sharma Sunil, Clive Sally, Hess Dagmar, Gelderblom Hans
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Lennerz V, Woelfel T, Forssmann U, Zieschang J, Gnad-Vogt U, Ochsenbein A, Knuth A, von Boehmer L, Hess D, Boehm S, Mach N, Sessa C, Gallerani E, Gross S, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014; 63:381-94.
Feb 2, 2014Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Feb 2, 2014Cancer Immunol Immunother 2014; 63:381-94
Lennerz Volker, Woelfel Thomas, Forssmann Ulf, Zieschang Juergen, Gnad-Vogt Ulrike, Ochsenbein Adrian F, Knuth Alexander, von Boehmer Lotta, Hess Dagmar, Boehm Steffen, Mach Nicolas, Sessa Cristiana, Gallerani Elisa, Gross Stefanie, Kaempgen Eckhart
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
Geisthoff U, Nguyen H, Hess D. Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann Hematol 2013
Jul 27, 2013Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
Jul 27, 2013Ann Hematol 2013
Geisthoff Urban W, Nguyen Ha-Long P, Hess Dagmar
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
Sep 20, 2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Sep 20, 2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib
Böhm S, Hess D, Gillessen Sommer S, Brändle M. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diabetes care 2010; 33:e82.
Jun 1, 2010Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib
Jun 1, 2010Diabetes care 2010; 33:e82
Böhm Steffen, Hess Dagmar, Gillessen Sommer Silke, Brändle Michael
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.
Apr 29, 2010Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Apr 29, 2010Case Rep Oncol 2010; 3:131-136
Hawle H, Hess Dagmar, Mueller A, Thürlimann Beat
Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Boehm S, Rothermundt C, Hess D, Jörger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009
Nov 26, 2009Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Nov 26, 2009Gerontology 2009
Boehm S, Rothermundt Christian, Hess Dagmar, Jörger Markus